Android app Apple app link

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

By Yahoo! Finance   |   2 weeks ago
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Wedbush initiated coverage on Zenas BioPharma, a clinical-stage biopharmaceutical company focusing on autoimmune disease therapies. ZBIO started trading on NASDAQ after raising $258.7 million in an IPO.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.